DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,112 filers reported holding DANAHER CORPORATION in Q4 2016. The put-call ratio across all filers is 0.26 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $17,239,408 | -4.1% | 68,975 | -4.3% | 0.14% | -2.8% |
Q1 2024 | $17,981,674 | +59.7% | 72,041 | +48.0% | 0.14% | +37.5% |
Q4 2023 | $11,259,746 | +20.9% | 48,664 | +29.7% | 0.10% | +1.0% |
Q3 2023 | $9,309,456 | +2181.7% | 37,523 | +2107.2% | 0.10% | +2475.0% |
Q2 2023 | $408,000 | +16.3% | 1,700 | +22.1% | 0.00% | 0.0% |
Q1 2023 | $350,840 | +30.1% | 1,392 | +37.0% | 0.00% | +33.3% |
Q4 2022 | $269,667 | +8.7% | 1,016 | +5.6% | 0.00% | 0.0% |
Q3 2022 | $248,000 | +19.8% | 962 | +18.0% | 0.00% | 0.0% |
Q2 2022 | $207,000 | +84.8% | 815 | +113.4% | 0.00% | +200.0% |
Q1 2022 | $112,000 | -69.1% | 382 | -65.3% | 0.00% | -75.0% |
Q4 2021 | $362,000 | -98.1% | 1,100 | -98.4% | 0.00% | -98.1% |
Q2 2021 | $18,581,000 | -10.8% | 69,239 | -25.2% | 0.22% | -19.2% |
Q1 2021 | $20,830,000 | +251.7% | 92,544 | +247.1% | 0.27% | +192.3% |
Q4 2020 | $5,923,000 | +6787.2% | 26,665 | +6599.7% | 0.09% | +9000.0% |
Q3 2020 | $86,000 | -39.4% | 398 | -50.6% | 0.00% | -66.7% |
Q2 2020 | $142,000 | +52.7% | 805 | +25.2% | 0.00% | +50.0% |
Q3 2019 | $93,000 | -7.0% | 643 | -30.3% | 0.00% | 0.0% |
Q3 2018 | $100,000 | +163.2% | 923 | +126.8% | 0.00% | +100.0% |
Q4 2017 | $38,000 | +65.2% | 407 | +51.9% | 0.00% | 0.0% |
Q3 2017 | $23,000 | -96.8% | 268 | -96.8% | 0.00% | -94.7% |
Q2 2017 | $712,000 | -31.4% | 8,428 | -30.6% | 0.02% | -29.6% |
Q1 2017 | $1,038,000 | -88.4% | 12,137 | -89.5% | 0.03% | -89.8% |
Q4 2016 | $8,971,000 | +2766.1% | 115,256 | +3392.6% | 0.27% | +1562.5% |
Q1 2016 | $313,000 | +192.5% | 3,300 | +164.8% | 0.02% | +300.0% |
Q4 2014 | $107,000 | +13.8% | 1,246 | +0.7% | 0.00% | 0.0% |
Q3 2014 | $94,000 | -96.5% | 1,237 | -96.4% | 0.00% | -96.3% |
Q2 2014 | $2,701,000 | -63.9% | 34,298 | -65.6% | 0.11% | -56.5% |
Q1 2014 | $7,472,000 | -12.3% | 99,626 | -9.7% | 0.25% | -3.1% |
Q4 2013 | $8,517,000 | +95.0% | 110,330 | +75.1% | 0.25% | +88.1% |
Q3 2013 | $4,368,000 | +9.6% | 63,009 | +0.1% | 0.14% | +7.1% |
Q2 2013 | $3,985,000 | – | 62,954 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |